Vixotrigine (original) (raw)
Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker. Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain. It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.
| Property | Value |
|---|---|
| dbo:abstract | Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker. Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain. It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued. (en) |
| dbo:casNumber | 934240-30-9 934240-35-4 (mesylate) |
| dbo:fdaUniiCode | QQS4J85K6Y |
| dbo:kegg | D11179 |
| dbo:pubchem | 16046068 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Raxatrigine.svg?width=300 |
| dbo:wikiPageExternalLink | http://adisinsight.springer.com/drugs/800027679 |
| dbo:wikiPageID | 43349052 (xsd:integer) |
| dbo:wikiPageLength | 4332 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1082988486 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Bipolar_disorder dbr:Voltage-gated_sodium_channel dbr:List_of_investigational_analgesics dbc:Analgesics dbc:Pyrrolidines dbr:Erythromelalgia dbr:Oral_administration dbr:Neuropathic_pain dbr:Clinical_trial dbr:Peripheral_nervous_system dbr:Trigeminal_neuralgia dbc:Enantiopure_drugs dbr:Analgesic dbc:Carboxamides dbc:Sodium_channel_blockers dbr:Central_nervous_system dbr:Binding_selectivity dbr:Mesylate dbr:Phases_of_clinical_research dbr:Nav1.7 dbr:Ion_channel_blocker dbr:Nav1.3 dbr:Lumbosacral_radiculopathy |
| dbp:atcPrefix | None (en) |
| dbp:c | 18 (xsd:integer) |
| dbp:casNumber | 934240 (xsd:integer) |
| dbp:casSupplemental | 934240 (xsd:integer) |
| dbp:chemspiderid | 13174481 (xsd:integer) |
| dbp:f | 1 (xsd:integer) |
| dbp:h | 19 (xsd:integer) |
| dbp:iupacName | -5 (xsd:integer) |
| dbp:kegg | D11179 (en) |
| dbp:n | 2 (xsd:integer) |
| dbp:o | 2 (xsd:integer) |
| dbp:pubchem | 16046068 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_administration |
| dbp:smiles | C1CCCN (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | JESCETIFNOFKEU-SJORKVTESA-N (en) |
| dbp:synonyms | Raxatrigine; CNV1014802; GSK-1014802; BIIB 074 (en) |
| dbp:unii | QQS4J85K6Y (en) |
| dbp:width | 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Analgesic-stub dbt:Analgesics dbt:Cn dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Abbrlink dbt:Fdacite dbt:Ion_channel_modulators |
| dcterms:subject | dbc:Analgesics dbc:Pyrrolidines dbc:Enantiopure_drugs dbc:Carboxamides dbc:Sodium_channel_blockers |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker. Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain. It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued. (en) |
| rdfs:label | Vixotrigine (en) |
| owl:sameAs | wikidata:Vixotrigine https://global.dbpedia.org/id/mbx6 |
| prov:wasDerivedFrom | wikipedia-en:Vixotrigine?oldid=1082988486&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Raxatrigine.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Vixotrigine |
| is dbo:wikiPageRedirects of | dbr:CNV1014802 dbr:Raxatrigine dbr:GSK-1014802 dbr:GSK1014802 dbr:GSK_1014802 dbr:CNV-1014802 dbr:CNV_1014802 |
| is dbo:wikiPageWikiLink of | dbr:List_of_investigational_analgesics dbr:CNV1014802 dbr:Raxatrigine dbr:GSK-1014802 dbr:GSK1014802 dbr:GSK_1014802 dbr:CNV-1014802 dbr:CNV_1014802 |
| is foaf:primaryTopic of | wikipedia-en:Vixotrigine |
